Actinic KeratosesNCT06385340
Investigation of the Effect of Lipikar Baume AP+M
A study testing Lipikar Baume AP+M in people with Actinic Keratoses, run by CentroDerm GmbH at 1 site in Germany.
Trial summary
Application of Lipikar Baume AP+M at least twice daily for 4 weeks on one of the two arms according to a randomization scheme The purpose of this study is to observe the skin barrier function, transepidermal water loss and microbial changes in study participants with actinic field damage of both arms. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Actinic Keratoses
- What is being tested?
- Lipikar Baume AP+M
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteGermany
- Study dates
- 23 Apr 2024to 30 Nov 2025
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male, female, diverse persons (> 18yo) who are capable of giving consent
- Female patients are eligible if the subject is not a woman of childbearing potential (WOCBP) or if she is postmenopausal (cessation of menstruation >12 months) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, total hysterectomy)
- Signed informed consent
- Diagnosis of at least 4 actinic keratoses of the the forearm and/or back of the hand (each arm)
- Olsen grade I, II and/or III
- Subjects with similar severity and number of AKs on each side symmetrically
- The study participant is in good general condition for his or her age and does not currently have any active diseases that, in the opinion of the investigator, justify exclusion from the study
Who cannot join
- Known or documented intolerance to any of the ingredients of Lipikar Baume AP+M
- Any planned AK treatment during the study
- Treatment of actinic keratoses in the application area within the past 3 Months (e.g. photodynamic therapy, topical 5-FU, diclofenac, imiquimod, cryotherapy etc.)
- Suspected invasive squamous cell cancer in the application area
- Chronic wounds, erosions, pre-existing infected skin or inflammation which, in the opinion of the investigator, are in need of treatment other than the study product
- Suspected non-compliance
Show all 14Show fewer
- Current or within the last 8 weeks given systemic cancer medication or systemic treatment with 5-Fluorouracil
- Any systemic immunosuppressant given within the 8 weeks prior to the study (e.g. systemic prednisolone, azathioprine etc.)
- Locally applied retinoids, steroids, or other prescribed externals in the 4 weeks prior to the start of the study that, in the opinion of the study physician, necessitate exclusion
- Products containing glycolic or alpha-hydroxy acids applied locally in the application area in the last 4 weeks
- Participation in another clinical trial
- Participation in a clinical study within the last 30 days
- Family members or colleagues of the investigator
- Participant is in a position or has a relationship with the investigator that presents a potential conflict of interest
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site, 1 recruiting
- Recruiting
CentroDerm GmbH
Wuppertal, North Rhine-Westphalia, 42287
Thomas Dirschka, Prof. Dr. med., 0049 (0) 202 629337 57, studien@centroderm.de
About this study
Official title: Investigation of the Effect of Lipikar Baume AP+M on Skin Barrier, Microbiome and AKASI of Participants With Actinic Keratoses and Field Cancerization of the Forearms and Hands
Application of Lipikar Baume AP+M at least twice daily for 4 weeks on one of the two arms according to a randomization scheme The purpose of this study is to observe the skin barrier function, transepidermal water loss and microbial changes in study participants with actinic field damage of both arms.
It's a randomized, evaluator blinded, intra-individual controlled study conducted in one center in Germany, in adult subjects having AK (grade I to III) lesions on the forearms and back of hands and meeting specific inclusion/exclusion criteria.
Read more
A total of 20 subjects will be enrolled.
The study design consists in 4-week evaluation period, with 2 visits per subject: Screening/Baseline (Day 0, Day 28 (end of Lipikar Baume AP+M application)).
- Conditions
- Actinic Keratoses
- Being tested
- Lipikar Baume AP+M
- Medical subject headings
- Keratosis, Actinic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lipikar Baume AP+MOther
- Lipikar Baume AP+M Application of Lipikar Baume AP+M at least twice daily for 4 weeks on one of the two arms according to a randomization scheme
| Study group | Role | What they receive |
|---|---|---|
| Lipikar Baume AP+M | Other | Application of Lipikar Baume AP+M at least twice daily for 4 weeks on one of the two arms according to a randomization scheme Receives: Other: Lipikar Baume AP+M |
| no intervention | No intervention | Application of Lipikar Baume AP+M at least twice daily for 4 weeks on one of the two arms according to a randomization scheme |
What is being measured
The primary outcome is the main question the study is designed to answer.
Skin hydration measured by Corneometrie
Corneometer® (Courage + Khazaka electronics GmbH, Cologne, Germany) is used to assess skin hydration after 28 days. The Corneometer® measures in arbitrary units from 0 (no water) - 120 (on water). The units are referred to as "Corneometer® units". In total there will be 3 measurements at each point (Actinic keratosis, perilesional, never by actinic keratosis affected skin/healthy). The average of the 3 measurements is calculated and day 0 and day 28 are compared.
Measured: Day 28
Transepidermal water loss measured by Tewameter®
Transepidermal water loss (in g/m2/h - TEWL) measured by Tewameter® (Courage + Khazaka electronics GmbH, Cologne, Germany). 3 measurements at each arm und lesion will be taken (Actinic keratosis, perilesional and never by actinic keratosis affected skin). The average of the 3 measurements is calculated and day 0 and day 28 are compared.
Measured: Day 28
Aktinic keratosis area and severity index (AKASI)
The AKASI is a standardized tool for the clinically adequate assessment of larger areas (1). The area, distribution, erythema, and thickening of actinic keratoses are evaluated according to Dirschka et al. and a score is calculated. The score is between 0-18. Average values of study participants of each study group will be compared (day 0, day 28).
- Dirschka T, Pellacani G, Micali G, Malvehy J, Stratigos AJ, Casari A, et al. A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index. J Eur Acad Dermatol Venereol. 2017;31(8):1295-302.
Measured: Day 28
S. aureus colonization and S. epidermidis colonization (application area)
- aureus colonization and S. epidermidis colonization is assessed after 28 days by skin swabs and qPCR. Quantification is based on fluorescence measurements taken in real time during a PCR cycle. Fluorescence increases in proportion to the amount of PCR product. At the end of a run (consisting of several cycles), quantification is performed in the exponential phase of the PCR using the fluorescence signals obtained. Mean Ct values (cycle threshold) of the study groups are given for qPCR.
Measured: Day 28
Subjects's skin aspect
The investigator will assess the subject's skin aspect on the following signs or symptoms: scarring, atrophy, induration, redness or change in pigmentation.
The Score is between 0 (poor) and 3 (Excellent). The investigator will assess the subjects skin aspect at day 28 for all lesions, that have disappeared. An anverage of the score is calculated for all lesions in each study group.
Measured: Day 28
Secondary outcomes (7)
Absolute lesion count by application site
Actinic keratoses that are clearly visible or palpably are counted at each study site (left and right arm and back of the hands).
Absolute lesion counts by application site will be compared (day 0 and day28).
Measured: Day 28
Olsen Grade evaluation: percentage of lesion with improvement at least 1 grade at D28 by application site
The percentage of lesions with an improvement of at least one grade (Olsen grade) at day 28 will be assessed.
For this the Olsen classification of each actinic keratosis should be recorded. This classification is based on a three-grade grading of the thickness of a single lesion and was first proposed by Olsen et al. Grade 1 describes a slightly palpable lesion, grade 2 a moderately thick and grade 3 a very thick and hyperkeratotic lesion. If actinic field cancerization is present, the highest Olsen grade in the area will be assessed.
Average Olsen Scores by application site of Day 0 and D28 will be compared.
Measured: Day 28
Number of new lesions on application area over the study period by application site
All new actinic keratoses in the study area are recorded by application site (left and right arm and back of the hands).
Day 0 and Day 28 will be compared concerning the average of new lesions by application site.
Measured: Day 28
Symptom severity score: percentage across individual scores at each visit by application site
A symptom score with a four-point Likert scale (absent, light, moderate, severe) is assessed as patient reported outcome (PRO). The symptom score includes four principal symptoms (itch, unpleasant burning, pain, tingling).
The paper questionnaire with 4 questions will be handed out to the patient at Day 0 and Day 28. The symptom score is assessed for botch arms separately. The average scores by application will be compared concerning the overall score and the individual symptom scores (itch, burning etc.) at day 0 and day 28.
Measured: Day 28
modified Treatment Satisfaction Questionnaire for Medication-9 (mTSQM-9)
To assess the general satisfaction with Lipikar Baume AP+M an according to the study procedures modified TSQM-9 will be applied. This is a questionnaire that has been evaluated for the evaluation of antihypertensive medications but can also be applied to dermatological diseases.
This includes nine questions with Likert-scaled answers to assess the satisfaction with the cosmetic.
As the TSQM-9 was developped for medical agents, we changed the word medicament to "cosmetic", to assess the score at day 0 and day 28. The average of score of day 0 and day 28 will be compared.
Measured: Day 28
Compliance (percentage of subjects using topical agents at all intended days, 90% of days or 75% of days)
A patient diary is used to assess the days on which Lipikar Baume AP+M was used.
The proportion of patients with at least 75% of days and >90% of days on which Lipikar Baume AP+M was used will be calculated.
Measured: Day 28
Pictures at all time points
Pictures of the forearms and back of the hands are taken to illustrate the effects of Lipikar Baume AP+M.
Measured: Day 28
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Apr 2024
- Study start23 Apr 2024
- Primary completion30 Oct 2025 (estimated)
- Study completion30 Nov 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Actinic KeratosesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- It's a randomized, evaluator blinded, intra-individual controlled study conducted in one center in Germany, in adult subjects having AK (grade I to III) lesions on the forearms and back of hands and meeting specific inclusion/exclusion criteria.
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- CentroDerm GmbH
- Sponsor type
- Research network
- Responsible party
- Sponsor
- Investigators
- Thomas Dirschka, Prof. Dr., Principal investigator, CentroDerm GmbH
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06385340
- Sponsor's protocol ID
- CentroDerm_LRP22003
- Status last verified
- Jul 2025
- First submitted
- 2 Apr 2024
- Last updated
- 11 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No